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ABSTRAK 
 
Tajuk:  
Mengukur kadar penapisan glomerulus di kalangan pesakit onkologi yang menerima 
kemoterapi Cisplatin : Perbandingan antara kaedah pengiraan kreatinin dengan kaedah 
99mTc-DTPA. 
Objektif: 
Menganalisa insiden kerosakan ginjal berikutan rawatan kemoterapi Cisplatin di kalangan 
pesakit onkologi melalui kaedah pengiraan kadar penapisan glomerulus sebelum dan selepas 
kemoterapi menggunakan persampelan plasma 99mTc-DTPA sebagai rujukan dan 
dibandingkan dengan kaedah pengiraan kreatinin dengan kaedah 99mTc-DTPA. 
Metodologi: 
Satu kajian prospektif yang melibatkan 33 pesakit yang telah dirujuk ke Jabatan Perubatan 
Nuklear, Hospital Pulau Pinang untuk skan 99mTechnetium-diethylenetriamine pentaasetic 
asid antara 1 February 2014 and 30 April 2015. Kajian ini telah dijalankan bagi menganalisa 
insiden kerosakan ginjal berikutan rawatan kemoterapi Cisplatin di kalangan pesakit  
onkologi melalui kaedah pengiraan kadar penapisan glomerulus sebelum dan selepas 
kemoterapi menggunakan persampelan plasma 99mTc-DTPA sebagai rujukan dan 
dibandingkan dengan kaedah pengiraan kreatinin dengan kaedah 99mTc-DTPA. Daripada 33 
pesakit yang dirujuk, hanya 21 orang sahaja yang layak dimasukkan ke dalam kajian ini.  
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Keputusan:  
Dari seramai 21 orang pesakit yang dikaji, 16 (76.2%) adalah lelaki manakala 5 (23.8%) 
adalah wanita. Usia purata pesakit adalah 55.1 tahun (10.80). Dos Cisplatin yg diberikan 
adalah sebanyak 75mg/m2per pusingan kemoterapi untuk 3 pusingan. Perbezaan purata GFR 
oleh PSC 2 sebelum dan selepas kemoterapi adalah sebanyak 13.38 (-4.60, 31.36) 
ml/min/1.73m2 (p 0.136). Daripada 21 pesakit, 3 orang telah didapati mengalami kerosakan 
buah pinggang akut yang didefinisikan sebagai GFR < 50ml/min/1.73m2. Jumlah ini telah 
membentuk peratusan sebanyak 14.3% daripada keseluruhan insiden kerosakan buah 
pinggang. Plot Bland-Altman telah menunjukkan hanya metod PSC 1 mematuhi metod PSC 
2. Intraclass Correlation Coefficients (ICC) pula menunjukkan metod PSC 1 memiliki 
kebolehpercayaan yang tinggi terhadap metod PSC 2 (p< 0.001). Manakala kaedah-kaedah 
lain yg menggunakan asas serum kreatinin dalam formula GFR seperti CG, MDRD dan 
CKD-EPI serta Gates menunjukkan tidak ada persetujuan serta kebolehpercayaan jika 
dibandingkan dengan metod PSC 2 (p> 0.05).  
Kesimpulan: 
Kaedah menggunakan radionuklid dalam menilai GFR adalah merupakan kaedah 
yang paling sensitif dalam mengesan kejadian kerosakan buah pinggang disebabkan oleh 
Cisplatin. Seramai 3 orang daripada sejumlah 21 orang pesakit telah didapati mengalami 
kerosakan buah pinggang akut (GFR < 50ml/min/1.73m2) oleh kedua dua metod PSC 1 dan 
PSC 2. Kaedah PSC 1 adalah kaedah yang boleh dipercayai dan digunapakai dalam penilaian 
GFR serta boleh boleh dijadikan pengganti kepada metod PSC 2. Kaedah-kaedah lain seperti 
CG, MDRD, CKD-EPI dan juga Gates tidak boleh digunapakai utk mengesan kejadian 
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kerosakan buah pinggang berikutan rawatan Cisplatin. Kami mengesyorkan penggunaan PSC 
1 utk penilaian GFR bagi pemantauan kes rawatan kemoterapi Cisplatin. 
ABSTRACT 
 
Topic: 
Estimating glomerular filtration rate in oncology patients receiving Cisplatin chemotherapy : 
Predicted creatinine clearance against 99mTc-DTPA methods  
 
Objective: 
To analyze the incidence of Cisplatin induced nephrotoxicity in oncology patients through 
GFR estimation pre and post chemotherapy using 99mTc-DTPA plasma sampling as 
reference method and to compare with predicted creatinine clearance and Tc-99m renal 
scintigraphy. 
 
Methodology/ Study Design: 
A prospective study of 33 patients referred to the Department of Nuclear Medicine, Hospital 
Pulau Pinang for 99mTc-DTPA scan between 1 February 2014 and 30 April 2015. This study 
was performed to analyze the incidence of cisplatin induced nephrotoxicity among the 
oncology patients via the radionuclide and creatinine-based method of GFR estimation. Out 
of 33 adults referred, only 21 are included in the study.  
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Results: 
From the 21 patients included in the study, 16 (76.2%) are male and 5 (23.8%) are female. 
The mean age of patients is 55.1 (10.80). The dose of Cisplatin given was 75mg/m2 for each 
cycle up to three cycles. The mean difference of GFR pre and post chemotherapy as given by 
the PSC 2 method was 13.38 (-4.60, 31.36) ml/min/1.73m2 (p 0.136). Of 21 patients, 3 were 
found to have severe nephrotoxicity (GFR < 50ml/min/1.73m2) contributing 14.3% of 
incidence. Bland-Altman plot showed only PSC 1 is in agreement with PSC 2 technique. 
Intraclass Correlation Coefficients (ICC) also showed that PSC 1 has high degree of 
reliability in comparison to PSC 2 method (p< 0.001). The rest of the methods, namely the 
CG, MDRD, CKD-EPI and Gates methods do not show reliability and agreement in 
comparison to PSC 2 method (p< 0.05).  
 
Conclusion: 
Radionuclide method for evaluating GFR is the most sensitive method for the 
detection of Cisplatin induced nephrotoxicity. 3 of 21 patients were found to develop severe 
nephrotoxicity (GFR < 50ml/min/1.73m2) in this small number of samples by both PSC 1 
and PSC 2 methods. PSC 1 method was found to be a reliable substitute of PSC 2. The rest of 
the methods, namely the CG, MDRD, CKD-EPI and Gates are not reliable for detection of 
early nephrotoxicity. We will recommend the use of one plasma sampling method (PSC 1) 
for GFR estimation in monitoring post Cisplatin chemotherapy patients. 
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The recent data published in 2011 which was based on GLOBOCAN 2008 indicates 
that the numbers of cancer cases are on the rise worldwide. Among the risk factors identified 
are aging and unhealthy life style. The data shows 12.7 million of cancer cases with 7.6 
million of deaths estimated to have occurred in 2008 (Ferlay et al., 2010, Jemal et al., 2011).  
Those are identified as solid tumours and the use of Cisplatin chemotherapy as neo-adjuvant 
treatment has been shown to have a higher cancer response by 2 to 3 fold compared to after 
radio-surgery (Stathopoulos, 2013).  
Cisplatin remains as one of the best anticancer agent for the treatment of solid tumour 
over the last 30 years (Stathopoulos, 2013). Cisplatin in its full name is known as 
dichlorodiamino platinum and had been used for the treatment of various malignancies 
involving the head and neck, lung, breast, liver, testis, ovarian and bladder (Kodama et al., 
2014a). Despite its well-known desirable effect on cancer treatment per se, its full therapeutic 
potential has been limited by its potential toxicity. Many articles reported that the incidence 
of nephrotoxicity following high dose cisplatin chemotherapy happens in the range of 20 to 
25% (Yao et al., 2007, Gonzalez et al., 2004). Since Cisplatin remains as a promising 
therapeutic anticancer therapy up to date, on-going researches are being done to develop 
concurrent renoprotective agent that can reduce the effect of nephrotoxicity. Numerous 
efforts are being done to evaluate other chemotherapeutic agents and targeted therapies that 
can be alternative to Cisplatin with more or less similar therapeutic effect but lesser toxicity 
(Stathopoulos, 2013). Injury to the kidney could happen even after a single dose of 50 to 
100mg/m2 of Cisplatin, however, most of the cases are reversible with conservative treatment 
of volume expansion or saline diuresis with early detection while a small percentage of 
patients will continue to have progressive decline in renal function. Worst case scenario has 
been described in the literature whereby repetitive courses of Cisplatin at high doses may lead 
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to irreversible kidney damage if it fails to be detected and treated at early stage (Yao et al., 
2007). 
To address this issue, current clinical practice requires close monitoring of the kidney 
function pre and post chemotherapy to anticipate any significant decline of renal function. 
Therefore, estimating the glomerular filtration rate (GFR) has been accepted at large as a 
parameter to represent the functional status of the kidney (Itoh, 2001). There are various 
techniques which has been proposed to estimate GFR using endogenous or exogenous 
markers, but the most important aspect in choosing which method to use will have to take 
into account the simplicity, cost and availability without compromising the accuracy of the 
result. The development of various techniques has taken place from calculating the 
endogenous to exogenous substances excreted by the kidneys over the years, and until today 
it is still well accepted that measurement of the inulin clearance for assessment of GFR 
remains as the gold standard. Nevertheless, this method has gained less popularity in view of 
its complexity and invasive procedures to perform. Therefore, since the era of 1970s, 
radionuclide techniques have been developed as an alternative to inulin for measurement of 
GFR (Filler, 2008).  
At present, the most frequent technique to assess bedside GFR is still by measuring 
the serum creatinine. The result is incorporated into various formulas in order to generate 
GFR. However, of note, the interpretation result of this method is susceptible to many 
variations by multiple non renal factors, namely the muscle mass, age, race and not forgetting 
the dietary intake (Millward et al., 1996). This holds true that in our centre, estimation of 
GFR using serum creatinine and Cockroft-Gault (CG) formula is still the preferred choice 
here in view of its simplicity to be performed bedside at an affordable cost. 
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The main aim for performing this study is to encourage early detection of 
nephrotoxicity post Cisplatin chemotherapy among the selected oncology patients. This is 
achieved via various methods for comparison namely the creatinine based method againts the 
99mTc-DTPA method. Radionuclide method has been shown to be a potential alternative to 
inulin (Biggi et al., 1995). With this, 99mTc-DTPA with two plasma sampling method (PSC 
2) has been chosen as the standard of reference. In this study, we attempt to evaluate the 
reliability of the creatinine based equations and 99mTc-DTPA single plasma sampling (PSC 
1) in comparison to the PSC 2. We also attempt to justify the use of PSC 1 as an alternative to 
PSC 2 in view of the less invasive technique with only single blood sampling without 
compromising the accuracy of the GFR reading. This is in accordance with the recent study 
conducted in 2010 which aim to find a simplified yet accurate way of determining GFR 
among children in order to reduce the physical and psychological trauma to the patients 
following repetitive blood sampling (Gutte et al., 2010). In order to evaluate possibility of 
nephrotoxicity at earlier stage, this study will be conducted in 3 stages; pre chemotherapy to 
get baseline GFR, post mid cycle chemotherapy (after 3 cycles of chemo) to measure how 
much fall in GFR from baseline and at post completion of 6 cycles of chemotherapy to 
further evaluate the trend in GFR reading. The ideal situation is to conduct this study before 
and after every Cisplatin dose with the intention to get serial GFR reading. However, due to 
limited resources and logistic problems, the justification of this study design is made based 
on an article published in 2010 to perform the test to at least post third chemotherapy for 
accurate detection of early kidney injury (Fatima N., 2010). 
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2.1   Brief anatomy of the kidney 
Figure 1.0 Front view of urinary tract                          Figure 2.0 Anatomy of the kidney 
(Adapted from www.slideshare.net on 1.8.2015)         (Adapted from www.slideshare.net on 1.8.2015) 
 
The kidneys are bean shaped organ located retroperitoneally that play important roles 
in vertebrates. They maintain body homeostasis such as regulation of blood pressure, 
electrolytes and acid-base balance as well as site for hormones production such as calcitriol, 
erythropoietin and renin.  
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Figure 3.0 Cross-sectional view of renal cortex and renal medulla  
(Adapted from www.slideshare.net on 1.8.2015)       
 
Figure 4.0 Anatomy of the nephron 
         (Adapted from www.slideshare.net on 1.8.2015)       
Inside kidney, there is one single basic structure and functioning unit known as 
nephron. Each nephron is made up of a filtering component namely the renal corpuscle and 
the renal tubule with specific functions for reabsorption and secretion. On the other hand, the 
renal corpuscle by itself is responsible for filtering out solutes from the blood and delivering 
water and small solutes to the renal tubule for further processing. This unique structure is 
made up of a glomerulus and Bowman’s capsule and it marks the beginning of the nephron’s 
initial filtering component (Tortora and Derrickson, 2009).  
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The glomerulus is made up of a tuft of capillary with blood supply coming from the 
afferent arteriole of the kidney circulation. In glomerulus, water and solutes will be filtered 
through the glomerular wall into the Bowman’s capsule and this is made possible by a 
pressure force known as glomerular blood pressure. This is where the glomerular filtration 
occurs in the kidney. In addition to that, the filtration of fluid from the blood in the 
glomerulus is done by the podocytes which forms the visceral inner layer of the Bowman’s 
capsule. Following this, the resulting glomerular filtrates will then undergoes further 
processing along the nephron to form the urine (Tortora and Derrickson, 2009).  
2.2. Overview of renal physiology 
 In the kidney, the single basic structure and functioning unit is known as nephron. It 
serves three important basic processes which are the glomerular filtration, tubular 
reabsorption and tubular secretion (Tortora and Derrickson, 2009). 
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2.2.1 Glomerular filtration 
 
Figure 5.0 Anatomy of the glomerulus 
(Adapted from www.slideshare.net on 1.8.2015) 
   
Fluid that enters the capsular space is known as glomerular filtrate. Filtration 
happens when there is a driving force to push the fluid and solutes out of the afferent 
arteriole through a membrane in the capillaries. On average, daily volume of 
glomerular filtrate in adults is 150 liters in female and 180 liters in male. Except for 
blood cells, platelet, most plasma proteins and any substance, which have larger 
diameter than the entry pores in the membrane, most substances in blood plasma can 
easily pass through the glomerular filter.  
For further information, there are 3 main pressures involved in glomerular 
filtration, namely the glomerular blood hydrostatic pressure, capsular hydrostatic 
pressure and blood colloid osmotic pressure. Each of them carries specific function. 
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Glomerular blood hydrostatic pressure promotes filtering out of the glomerular 
capillaries into Bowman’s capsules whereas capsular hydrostatic and blood colloid 
osmotic pressure force the filtration from the capsules into the glomerular capillaries. 
Glomerular filtration rate is defined as the amount of filtrate formed in both kidneys 
per minute. The rate itself is determined by renal auto regulation, neural and hormonal 
regulation. 
2.2.2. Tubular reabsorption and secretion 
Any substances which are needed by the body will be reabsorbed back into the 
blood and any subtances which are no longer needed will be secreted into the tubule 
and excreted out of the body. For better understanding, reabsorption denotes the 
process of absorbing back the substances from the renal tubule into the blood stream 
whereas secretion denotes the process of excretion of substance from the blood into 
the renal tubule.  
2.3. Evaluation of kidney function 
 Assessing the kidney function requires evaluation of both quality and quantity 
endogenous substance such as urea and creatinine in the blood as well as the urine level. 
GFR, being the most popular marker of kidney function, is resembling the  number of 
functioning nephrons. This means that GFR will be reduced in case of reducing functioning 
renal mass.  
 2.3.1 Glomerular filtration rate (GFR) 
 GFR has been largely used as a measure of kidney function in clinical practice 
and it represents the volume of fluid filtered through the nephrons per unit time during 
formation of the urine (Schwartz and Furth, 2007).  It is said to be the best overall 
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measure of renal function in both healthy or diseased kidney (Smith, 1951). The 
normal level of GFR varies according to age, sex and body size. In young adults, it 
measures approximately 120 to 130ml/min/1.73m2 and this value reduces with age. 
Some other author has published the reference range of  GFR in adulthood to be 
approximately 105ml/min/1.73m2 of BSA (Levey et al., 2003). Although declining 
GFR value with age is considered part of normal aging process (Lindeman et al., 
1985), this factor has been found to be independent predictor of adverse sequelae, for 
example death or cardiovascular diseases (Manjunath et al., 2003). Therefore, the 
prevalence of chronic kidney disease by definition increases with age in view of the 
adverse outcomes associated to it. There is estimated 17% of the elderly aged above 
60 years old have GFR of less than 60ml/min/1.73m2 (Coresh et al., 2003).  This is an 
important point to be taken pertaining to the treatment option for chemotherapy and 
associated GFR level since the risk of developing carcinoma is also increasing with 
age. In children, GFR value slowly increases approaching the adult value over the 
first 2 years of life (Murray et al., 2013).  
 In clinical practice, the measurement of GFR has may uses which include 
evaluation and monitoring of kidney in chronic renal disease, during the course of 
administration of nephrotoxic  drugs, calculation of  myelotoxic chemotherapy drug 
doses that is excreted through the glomerular filtration, potential renal donor 
evaluation,  single kidney renal function evaluation, pre and post-operative follow up 
as well as prediction or assessment for the need of dialysis (Murray et al., 2013). 
 There are many options available to measure GFR and many methods are 
developed to meet this purpose using either endogenous or exogenous markers. The 
main interest of this study is to show the use of radionuclide method as a reliable GFR 
marker to detect evidence of nephrotoxicity following Cisplatin chemotherapy. 
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Radionuclide method has been shown to exhibit a comparable result and can be an 
alternative to the cumbersome inulin measurement in daily practice (Fawdry and 
Gruenewald, 1987, Rehling and Thamdrup, 1984). 
 GFR normalization is an important component to be performed in obtaining 
the final measurement. It is done to eliminate the individual variation from patient to 
patient pertaining to the different renal masses in order to establish the reference value 
across the individuals with different demographic characteristics (Murray et al., 
2013). There are two ways of performing GFR normalization; one is via Body Surface 
Area (BSA) method which is the most widely used method in clinical practice and the 
other one is the Extracellular Fluid Volume (ECV) which is less popular compared to 
the former method. Though BSA is the preferred method, there is an issue that comes 
along with it in which the physiologic relevance has been questioned (Turner and 
Reilly, 1995). In opposed to ECV method, it has been said to have a better 
dimensional relationship (volume- based) to GFR (Brøchner-Mortensen, 1980) and 
has gained more superiority against BSA method especially in children (Bird et al., 
2003). 
 The BSA and ECV normalizations equations are as follows: 
Figure 6.0 BSA and ECV equations 
(Adapted from Assessment of glomerular filtration rate measurement with plasma sampling:  
A technical review, Journal of nuclear medicine technology 2013 41(2): 67-75)) 
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where GFRBSA is in ml/min/1.73m2, GFRECV is in ml/min/12.9, BSA is in m2 and 
ECV is in litres. 
The two most commonly used  BSA estimation methods are the Dubois formula for 
adults (Du Bois and Du Bois, 1989) and the Haycock formula for both adult and 
children (Haycock et al., 1978). Both formulas area given as follows:  
 For Dubois formula, 
 
 For Haycock formula, 
 
Figure 7.0 Dubois and Haycock’s equations 
(adapted from Assessment of glomerular filtration rate measurement with plasma sampling:  
A technical review, Journal of nuclear medicine technology 2013 41(2): 67-75) 
where BSA is in meters squared, height is in centimetres and weight is in kilograms. 
 
 2.3.2 Effective  renal plasma flow (ERPF) 
 ERPF is another way of quantifying renal function other than GFR. ERPF is  a 
technique used to measure renal plasma flow thus estimating the renal function. It is 
measured using plasma clearance technique. Paraaminohippurate (PAH) is the best 
substance to measure ERPF with the extraction ratio nearly 1. Historically, I-131 OIH 
and I-123 OIH have been used to quantify ERPF whereby the urinary clearance of I-
131 OIH is approximately 85% of PAH. However, at present 99mTc-MAG3 has been 
used to replace hippuran.  Nevertheless, its efficacy for ERPF measurement has been 
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documented at about 60% of hippuran since it does not undergo glomerular filtration 
and slightly reduced level of tubular secretion. However, a lot of studies has been 
conducted and prove that 99mTc-MAG3 is able to produce an accurate ERPF result 
once corrected for the different extraction fraction (Ziessman et al., 2013). 
 
 2.3.3 Exogenous GFR markers 
 There are few exogenous substances which can be used for measurement of 
GFR. Among them are the inulin and the radioactive tracers such as the 99m-Tc 
DTPA and 51-Cr EDTA. Inulin, a group of naturally occurring polysaccharides 
produced by many types of plants, has the properties of an ideal tracer. It is neither 
secreted nor reabsorbed at the nephron allowing accurate GFR to be calculated.  It is 
the gold standard for measuring GFR but is rarely used clinically due to its technical 
difficulty, expensive, time consuming, require multiple urine samples and is 
problematic to be done in patients with urologic disease and in children.  Though it 
still remains as the gold standard method, it has lost its popularity due to its 
cumbersome procedure and technically difficult to be performed (Murray et al., 
2013).  
 Radionuclide method using plasma sample clearance has been found to 
produce accurate GFR measurement (Brøchner-Mortensen, 1978). However, Itoh  et. 
al concluded that this technique is laborious and therefore its use is reserved for 
specific indication that strictly requires accurate quantification of renal function (Itoh, 
2003). After all, we need to understand that the ideal characteristics of tracer 
properties used in GFR measurement shall include:  
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i) It undergoes only glomerular filtration and thus has identical plasma and 
urinary clearance.    
ii) It has a low molecular weight and small molecular size to allow free filtering 
through the glomerular membrane. 
iii) It has no entry into the intracellular space.   
iv) It has no interference with renal function.    
v) It has no extrarenal excretion or clearance to other organs.   
vi) It has no tubular secretion or absorption.    
vii) It has no nephrotoxicity. 
 Theoretically, a tracer that follows any processes other than glomerular 
filtration is not an ideal tracer and the resulting GFR is not equal to its plasma 
clearance. Those processes include radionuclide dissociation, metabolic degradation, 
plasma protein binding, tubular reabsorption and secretion. This phenomenon may 
lead to inaccuracy in GFR reading resulting from unwanted retention or clearance of 
the tracer. However, in real clinical practice, it is almost impossible to have an ideal 
tracer exactly as discussed above. Nevertheless, we still have the option of using near 
ideal properties to deal with the difficulty and impracticality of using an ideal tracer 
(Murray et al., 2013).    
 Radionuclide based techniques allow for the rapid and reliable measurement 
of GFR from plasma samples taken following IV bolus of radiotracer (Kuster, Cristol 
et al. 2014). The tracer diffuses across the capillary endothelium and between 
intravascular and extra vascular spaces and mixes throughout the extra vascular fluid 
volume (ECV). GFR can be measured through the quantification of plasma and 
standard-volume sample activity using a gamma counter. These techniques hold the 
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central assumption that the tracer is cleared solely by glomerular filtration (Murray et 
al., 2013). 
 Two of the most frequently used tracers for GFR measurement with near ideal 
properties are Cr-51 EDTA and Tc-99m DTPA. Cr-51 allows more time between the 
drawing of blood and counting of the samples due to its relatively long half-life of 
27.7 days. However, the disadvantage of using Cr-51 is that not only it is expensive, it 
also has associated tubular reabsorption as well as issue in handling storage of Cr-51 
waste. A reported practical advantage for Cr-51 EDTA studies is that any plasma 
samples with an existing Tc-99m concentration can be left to decay until no Tc-99m 
remains before processing. Whereas for Tc-99m DTPA, it has the advantage that it is 
readily available and can be produced with a Mo-99/Tc-99m generator already in 
house for diagnostic work thus reducing expenses. Its disadvantage is that processing 
is required within 24 hours of taking plasma samples due to its shorter half life of 6 
hours (Murray et al., 2013).  
There is still a big challenge to get simple yet accurate method for GFR 
determination. Another radionuclide technique using gamma camera uptake known as 
Gates method where GFR is calculated without blood or urine sampling. This method 
has been the most common in routine setting, although diagnostic accuracy of gamma 
camera is debatable (Itoh, 2003). Due to that the same author has conducted a study to 
assess the clinical validity of single-sample methods and gamma camera uptake 
methods with Tc-99m DTPA for the estimation of GFR in patients with various 
degree of renal dysfunction. The reference for the “true” GFR (GFRt) was determined 
from plasma clearance by means of the two-compartment model curve fitting 10 
plasma samples. The author found out that the single sample method in GFR 
≥30ml/min was more accurate than the gamma camera method, and the gamma 
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camera method was accurate than 24hour creatinine clearance.  Due to that he 
concluded that the single sample method should be recommended for the accurate 
determination of the GFR with Tc-99m DTPA in a patient with mild to moderate 
renal dysfunction (Itoh et al., 2000). The same author again conducted another study 
aiming towards the assessment of clinical accuracy of single, two and multi sample 
methods. He proposed the use of single sample method at 180 min as the first choice 
in a routine practice in view of its accuracy and technical simplicity. The two-sample 
method at 120 min and 240 min is chosen selectively for a patient with severe renal 
failure where serum creatinine at the time of the test may help for the choice of either 
the single or the two-sample method (Itoh et al., 2000). This result is in agreement 
with the study conducted by Christensen and Groth among cancer patients referred for 
routine determination of Tc-99m DTPA clearance by comparing single and multiple 
plasma sample methods. The authors have concluded that the single method is 
accurate and that may prove useful as a routine method provided that the method is 
not used in patients with Tc-99m DTPA clearance less than 30ml/min and the plasma 
samples drawn between 180 to 300 min (Christensen and Groth, 1986).  
In this study, the two plasma sampling method using Tc-99m DTPA has been 
used as the standard for comparison among other methods which are creatinine-based 
GFR. Its principle of GFR measurement is based on clearance of plasma radioactivity 
via single and two-blood sample using the well counter where by the blood was taken 
at 60 and 180 minutes post tracer injection and to compare with the clearance of 
radioactivity from plasma sampling taken at 180 minutes alone. Comparing to the 
study conducted by Waller and Keast, their measurement of GFR was taken from 
plasma radioactivity using single and two blood samples, tissue clearance with probe 
detectors, renal uptake and excretion using scintillation camera and combination of 
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single blood sample and external detector clearance rate. Those methods were 
compared with multiple plasma sampling where blood was taken at 1 hour post 
injection and again every 30 min for a period of 4 hour. Apart from comparing the 
individual accuracy of each method as well as its suitability for routine clinical use in 
the assessment of adult patients, the study was also done to assess how much data 
reduction was possible without impairing the accuracy of the result. From the analysis 
using 2 blood samples, the correlation with multiple-point plasma clearance was 
excellent, and in fact improved results was obtained by using the later blood samples. 
This was probably due to incomplete equilibration at earlier sampling times and this 
can be reduced by increasing the time between the samples. The results for single 
blood sample show inferior correlation compared with two blood samples taken at 
around the same time. However, the correlation improves when the time of sampling 
post injection is longer, reaching an optimum between 3 and 4 hour then deteriorating 
significantly at 5 hour. Meanwhile, the author did not recommend the use of less 
invasive external counter clearance rate without blood sampling since it does not 
correlate well enough with GFR (Waller et al., 1987).  
On average, most of the studies conducted supported the use of single plasma 
sample of Tc-99m DTPA method for accurate measurement of GFR provided the 
GFR measured is ≥30 ml/min. This means that in view of its technical simplicity, time 
and cost saving, it is acceptable to implement this method in the clinical practice to 
evaluate kidney function where GFR is ≥ 30ml/min.  
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2.3.3.1 Clearance characterization 
 2.3.3.1.1 GFR Introduction 
Plasma clearance assumes the biexponential model with 2 
distinct compartments. It represents the fixed flow rates between constituent 
compartments. This can be illustrated further in the diagram below: 
 
Figure 8: Two and three compartment model 
(adapted from Assessment of glomerular filtration rate measurement with plasma sampling:  
A technical review, Journal of nuclear medicine technology 2013 41(2): 67-75) 
  
After mixing has occurred between the 2 compartments, the 
slope of the clearance reflects solely renal clearance.  
2.3.3.1.2 One-Compartment Characterization 
Briefly, in this model, only the late exponential is 
characterized, and published corrections can be used to fill up for the missing 
early-compartment area under the curve (AUC). Only 2 to 4 samples are 
needed to calculate the GFR and this method is referred as slope intercept 
method. 
The intercept of the late exponential is interpreted as 
instantaneous concentration of the tracer at the time of injection; instantaneous 
